Next Century Growth Investors Decreased Its Aerie Pharmaceuticals (AERI) Position; Petmed Express (PETS) Sentiment Is 1.38

February 21, 2018 - By Ellis Scott

Next Century Growth Investors Llc decreased Aerie Pharmaceuticals Inc (AERI) stake by 26.94% reported in 2017Q3 SEC filing. Next Century Growth Investors Llc sold 37,197 shares as Aerie Pharmaceuticals Inc (AERI)’s stock declined 8.47%. The Next Century Growth Investors Llc holds 100,887 shares with $4.90 million value, down from 138,084 last quarter. Aerie Pharmaceuticals Inc now has $2.06 billion valuation. The stock decreased 3.14% or $1.7 during the last trading session, reaching $52.5. About 303,611 shares traded. Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has risen 180.20% since February 21, 2017 and is uptrending. It has outperformed by 163.50% the S&P500.

PetMed Express, Inc. and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company has market cap of $954.65 million. The firm markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats to retail customers. It has a 27.57 P/E ratio. It provides non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, thyroid, diabetes, pain medications, antibiotics, and other specialty medications, as well as generic substitutes.

Investors sentiment increased to 1.73 in Q3 2017. Its up 0.56, from 1.17 in 2017Q2. It is positive, as 14 investors sold AERI shares while 41 reduced holdings. 26 funds opened positions while 69 raised stakes. 34.42 million shares or 8.89% more from 31.61 million shares in 2017Q2 were reported. Bancorporation Of Montreal Can holds 513 shares. Loomis Sayles Communication LP stated it has 0.03% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Tudor Et Al holds 0.01% or 11,010 shares in its portfolio. Hap Trading Limited Liability Corporation holds 14,880 shares or 0.03% of its portfolio. Susquehanna Llp holds 0% or 56,600 shares. 29,400 are owned by Benchmark Cap. Oppenheimer Asset has 182 shares for 0% of their portfolio. Paloma Prtnrs Mngmt owns 5,573 shares. Aqr Management Limited holds 35,078 shares. Citadel Limited holds 0.01% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) or 204,321 shares. Deerfield Management reported 1.39% stake. Consulate invested in 0.49% or 18,500 shares. Kazazian Asset Mngmt Limited Liability Co stated it has 0.87% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Hanseatic Ser Inc holds 16 shares. Credit Suisse Ag reported 0.01% stake.

Analysts await Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) to report earnings on March, 6. They expect $-1.47 earnings per share, down 68.97% or $0.60 from last year’s $-0.87 per share. After $-0.89 actual earnings per share reported by Aerie Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 65.17% negative EPS growth.

Next Century Growth Investors Llc increased Boingo Wireless Inc (NASDAQ:WIFI) stake by 309,818 shares to 913,967 valued at $19.53M in 2017Q3. It also upped Norwegian Cruise Line Holdings (NASDAQ:NCLH) stake by 15,524 shares and now owns 19,778 shares. Marten Transport (NASDAQ:MRTN) was raised too.

Among 15 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 15 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aerie Pharmaceuticals had 47 analyst reports since August 7, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) rating on Wednesday, October 11. Cantor Fitzgerald has “Buy” rating and $62.0 target. The firm earned “Strong Buy” rating on Wednesday, September 14 by Raymond James. The firm earned “Buy” rating on Tuesday, August 1 by Canaccord Genuity. On Friday, August 7 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The rating was maintained by Needham with “Buy” on Thursday, September 15. The firm has “Outperform” rating by RBC Capital Markets given on Thursday, September 15. The company was maintained on Thursday, November 16 by Cantor Fitzgerald. The firm has “Buy” rating by Cowen & Co given on Wednesday, August 2. Canaccord Genuity maintained the stock with “Buy” rating in Wednesday, September 20 report. The firm has “Buy” rating given on Thursday, November 9 by Cowen & Co.

Analysts await PetMed Express, Inc. (NASDAQ:PETS) to report earnings on May, 14. They expect $0.43 EPS, up 16.22% or $0.06 from last year’s $0.37 per share. PETS’s profit will be $8.76 million for 27.25 P/E if the $0.43 EPS becomes a reality. After $0.44 actual EPS reported by PetMed Express, Inc. for the previous quarter, Wall Street now forecasts -2.27% negative EPS growth.

Since January 1, 0001, it had 0 insider purchases, and 5 insider sales for $3.80 million activity.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: